May 26, 2021

A Philadelphia company developing what it describes as the first "electrically sensitive imaging agent" for the heart has raised more than $4 million in an oversubscribed Series A financing. Sonnest Inc. is developing technology created by physicians and researchers at Drexel University. 

The company’s equity financing was led by the SWAN Impact Network, Robin Hood Ventures and the Texas Halo Fund, and included a number of doctors and prominent angel investors. Sonnest plans to use the money to advance its lead product, Electrast, into the clinic. Electrast is a voltage-activated ultrasound imaging drug for myocardial perfusion testing to determine how well blood is flowing through the heart muscle and how well the heart muscle is pumping.

Read Full Article